Related by context. All words. (Click for frequent words.) 69 Combination REOLYSIN R 69 Hormone Refractory Prostate Cancer 66 Phase 2b Clinical Trial 66 Initiate Phase 66 Patients Treated With 66 Safinamide 65 Adjuvant Treatment 65 Trial Evaluating 65 Begins Dosing 64 mitoxantrone plus 64 Meets Primary Endpoint 64 chemoradiation therapy 64 Antitumor Activity 64 Advanced Melanoma 64 Phase 2b Study 64 RECORD1 64 metastatic malignant 64 Parathyroid Hormone 63 Soft Tissue Sarcoma 63 Metastatic Melanoma 63 Stage IIB 63 Pivotal Phase III 63 oropharyngeal candidiasis OPC 63 Phase IIb Trial 63 HER2 Positive 63 Aflibercept 63 Achieves Primary Endpoint 63 Complicated Skin 63 Prednisone Against Refractory 63 Relapsed Refractory 63 Peginterferon alfa 2b 63 Oral Fingolimod 63 Brentuximab Vedotin SGN 63 metastatic pancreatic 63 Systemic Sclerosis 63 metastatic colorectal 63 SPRYCEL ® 63 FDA APPROVES 63 5 fluorouracil leucovorin 63 Improves Outcomes 63 recurrent metastatic 62 Intravitreal 62 pediatric pontine glioma 62 TO AVOID PREGNANCY WHILE 62 Clinical Trial Results 62 Prolongs Survival 62 IMPACT DCM 62 Investigational Oral 62 resistant hormone refractory 62 bone marrow reticulin deposition 62 Dose Ranging Study 62 lexidronam injection 62 Shows Efficacy 62 including acne photodamage 62 Amgen Neulasta R 62 Pivotal Clinical Trial 62 receiving chemoradiation therapy 62 EMD # 62 Patient Enrollment 62 Tyrosine Kinase Inhibitor 62 R Saizen R 62 LHRH receptor positive 62 Phase 1b clinical trials 62 IN PATIENTS WITH 62 Investigational Treatment 62 recurrent malignant glioma 62 Refractory Hodgkin Lymphoma 62 Randomized Phase II 62 HER2 Positive Breast Cancer 62 Presents Positive 62 Demonstrates Positive 61 Severe Sepsis 61 alfa 2a 61 evaluating Prochymal 61 GOUT 61 Receives Orphan Drug Designation 61 generation purine nucleoside 61 PEG IFN 61 toenail onychomycosis 61 assessing T DM1 61 Efficacy Results 61 Relapsing Remitting Multiple Sclerosis 61 orally inhaled migraine 61 biliary tract cancer 61 Sudhir Agrawal D.Phil 61 SNT-MC#/idebenone 61 systemic anaplastic large 61 Antitumor activity 61 Zybrestat 61 Phase 2b Trial 61 Novel Oral 61 R abatacept 61 Pooled Analysis 61 Xeloda ® 61 humanized interleukin 6 61 arthritis PsA 61 Completes Patient Enrollment 61 Bayer Nexavar 61 Demonstrates Efficacy 61 Phase III Trial 61 Fluorouracil 61 Cutaneous T 61 Vitrasert R 61 phase IIb study 61 Initiates Phase III 61 epirubicin cyclophosphamide 61 phase IIb III 61 Phase #b/#a clinical 61 dual endothelin receptor antagonist 61 Bosutinib 61 Successfully Completes Phase 61 Initiates Phase II 61 Vascular Disrupting Agent 61 MetroGel 61 Initiated Phase 61 myelodysplastic myeloproliferative diseases 61 cell carcinoma RCC 61 Percutaneous vertebroplasty 61 Previously Treated 61 demonstrated antitumor activity 61 neutropenic sepsis 60 Node Positive 60 evaluating tivozanib 60 refractory chronic lymphocytic 60 Hsp# Inhibitor 60 Study Evaluating 60 Initiates Clinical Trial 60 Pivotal Study 60 metastatic GIST 60 Randomized Phase 60 Diabetic Macular Edema DME 60 Omacetaxine 60 Amgen Neulasta ® 60 Phase IIa Clinical Trial 60 Renal Cell Carcinoma 60 Kamada AAT 60 anti PlGF 60 Preclinical Models 60 Pivotal Phase 60 Kit CD# positive 60 essential thrombocythemia ET 60 RCW breast cancer 60 IIa Clinical Trial 60 Submits NDA 60 occlusion PAO 60 Folfox 60 Presents Preclinical Data 60 II Clinical Trial 60 ® lenalidomide 60 Cell Lymphoma 60 TNFerade TM 60 Initiates Enrollment 60 Shows Promising 60 LymphoStat B TM 60 Patients Receiving 60 Proc Am Soc 60 keloid scarring 60 Phase III Clinical Trial 60 Paclitaxel Carboplatin 60 Skin Structure Infections 60 LBH# 60 deep venous thromboses 60 paclitaxel poliglumex 60 transthyretin TTR mediated amyloidosis 60 Phase IIb Clinical Trial 60 Endometrial 60 antibody MAb 60 malignant ascites 60 Phase Ib Clinical Trial 60 exocrine pancreatic insufficiency EPI 60 Phase 2a Trial 60 mecasermin rDNA origin 60 MKC# MT 60 Myelodysplastic Syndrome MDS 60 miconazole Lauriad ® 60 pan histone deacetylase 60 Dose Escalation 60 Heterozygous Familial Hypercholesterolemia 60 GW# [003] 60 PEGylated Fab fragment 60 rheumatoid arthritis RA psoriatic 60 interferon beta 1a infertility 60 Randomized Study 60 IL# PE#QQR 60 Long Term Efficacy 60 midstage clinical 60 5 FU leucovorin 60 NSABP B 60 Squamous Cell Carcinoma 60 retinal vein occlusion induced 60 vinorelbine tartrate 60 Successfully Treats 60 catheter occlusion 60 fallopian tube cancers 60 CIMZIA TM certolizumab pegol 60 LymphoStat B belimumab 60 Newly Diagnosed Multiple Myeloma 59 ® bortezomib 59 #-# Full Text 59 including eniluracil ADH 59 radiation enteritis 59 forodesine 59 ACTEMRA TM 59 oral ridaforolimus 59 Pemetrexed 59 Proxinium TM 59 heFH 59 Bazedoxifene 59 Alocrest 59 investigational oral hepatitis C 59 recurrent squamous cell carcinoma 59 naïve HCV 59 Chronic Hepatitis C 59 sarcoma melanoma 59 Annamycin 59 Clinical Trial Evaluating 59 NAVISTAR R 59 paclitaxel Taxol R 59 Degarelix 59 Pegylated Interferon 59 recurrent herpes labialis 59 Renal Cancer 59 Phase 2a Clinical Trial 59 Oral Calcitonin 59 metastatic renal 59 Vicriviroc 59 thetreatment 59 IND Application 59 Commences Phase 59 Confirmatory Phase 59 Acute Myeloid Leukaemia AML 59 Shows Promise Against 59 approved incretin mimetic 59 unresectable HCC 59 Ozarelix 59 icatibant 59 Advanced Solid Tumors 59 Pegloticase 59 ongoing Phase 1b 59 Cannabinor 59 Stereotactic Body Radiation Therapy 59 steroid refractory 59 Motexafin Gadolinium 59 GVAX ® 59 mapatumumab 59 Files IND 59 indolent follicular non 59 cisplatin gemcitabine 59 Roche Herceptin 59 Unstable Angina 59 APPRAISE 59 hereditary antithrombin deficient 59 MKC# 59 RANK Ligand inhibitor 59 relapsed MM 59 non resectable metastatic 59 Hylan GF 59 docetaxel Taxotere ® 59 Loceryl ® 59 Clolar ® 59 oral clodronate 59 novel VDA molecule 59 oral prodrug 59 Improves Survival 59 Castration Resistant Prostate Cancer 59 BRIM2 59 Slows Progression 59 Phase IIIb clinical 59 3 registrational trial 59 Efficacy Trial 59 ritonavir boosted atazanavir 59 AN# topical anti 59 Novel Inhibitor 59 Overactive Bladder OAB 58 trial evaluating PRX# 58 Bevacizumab Avastin 58 registrational Phase 58 Antigen Specific 58 nasal decolonization 58 Darinaparsin 58 Known hypersensitivity 58 Single Dose 58 Acute Renal Failure 58 Preclinical Study 58 Phase Ib IIa 58 HuMax EGFr 58 SUCCEED trial 58 paclitaxel carboplatin 58 initiated Phase Ib 58 Pharmacokinetics PK 58 drug Treanda 58 BCG refractory carcinoma 58 R vitespen 58 ENDEAVOR III 58 refractory colorectal cancer 58 diarrhea fatigue asthenia 58 phase IIIb 58 ATRA IV 58 Relapsing Multiple Sclerosis 58 CYT# potent vascular disrupting 58 Temsirolimus 58 treatment naïve genotype 58 SUTENT ® 58 Completes Enrollment 58 hoFH 58 IIb clinical trial 58 humanized therapeutic 58 cutaneous lupus 58 Pivotal Phase II 58 VEGFR2 inhibitor 58 Ferinject R 58 lung esophageal 58 Granted Orphan Drug 58 hypertrichosis occurred 58 Mg Usa 58 gemcitabine carboplatin 58 Cloretazine ® 58 Non Alcoholic Steatohepatitis 58 Relapsed Multiple Myeloma 58 non resectable 58 atypical Hemolytic Uremic Syndrome 58 novel antimitotic agent 58 Cimzia TM 58 stage IIIb 58 Diabetic Foot Ulcer 58 immune globulin intravenous 58 Flu Cy 58 Aeolus Pharmaceuticals Announces 58 ZOLINZA 58 Effectively Treats 58 azilsartan medoxomil 58 SinuNase ™ 58 Slow Progression 58 follicular Non Hodgkin 58 See CLINICAL PHARMACOLOGY 58 Femara letrozole 58 Eluting Stent 58 monoclonal antibody conjugated 58 morphometric vertebral fractures 58 Anthracycline 58 budesonide foam 58 SUPPRELIN R LA 58 Mycophenolate Mofetil 58 pharmacokinetic PK study 58 randomized Phase IIb 58 myocardial infarction ventricular fibrillation 58 irinotecan doxorubicin oxaliplatin paclitaxel 58 RhuDex TM 58 receiving XGEVA 58 virus HCV protease inhibitor 58 Onyx Pharmaceuticals Announces 58 dose escalation clinical 58 Predict Response 58 Androxal TM 58 superficial basal cell carcinoma 58 lintuzumab SGN 58 doxorubicin cyclophosphamide 58 refractory metastatic colorectal cancer 58 First Patient Dosed 58 cough dyspnea 58 Acute Exacerbations 58 chronic myeloid 58 non splenectomized 58 BRAF mutant 58 adjuvant cisplatin 58 Quinamed 58 Patients Suffering 58 Drug Fails 58 Bayer HealthCare Onyx Pharmaceuticals 58 vitreous floaters 58 Fulvestrant 58 Zalypsis 58 epoetin alpha 58 Adjuvant Chemotherapy 58 Renal Impairment 58 Chronic Sinusitis 58 Irinotecan 58 Darusentan 58 fosbretabulin 58 liposomal amphotericin B 58 Central Retinal Vein 58 influenza BCX# purine nucleoside 58 itraconazole Sporanox 58 pain palliation 58 FUSILEV enhances 58 Demonstrates Sustained 58 Albuferon TM 58 Chronic Myelogenous Leukemia CML 58 Synta Announces 57 Pemphigus Vulgaris 57 cyclophosphamide doxorubicin vincristine 57 TNF Tumor Necrosis Factor 57 Cancer Incidence Mortality 57 Dupuytren Contracture 57 sunitinib Sutent 57 #mg/#mg 57 renal artery stenting 57 Toxicities 57 External Beam 57 See WARNINGS 57 Treatment Naive Patients 57 Dose Finding 57 multicenter prospective 57 Multiple Ascending Dose 57 diarrhea predominant irritable 57 fistulizing Crohn disease 57 corticosteroid dexamethasone 57 Metastatic Prostate Cancer 57 Pivotal Trial 57 treatment naive genotype 57 headache nasopharyngitis 57 Benign Prostatic Hyperplasia BPH 57 uremic pruritus 57 hormone refractory metastatic prostate 57 Commonly prescribed 57 J Am Acad 57 metastatic castration resistant 57 Vidaza ® 57 Renal Cell Cancer 57 Controlled Study 57 BN# [004] 57 PEGINTRON TM 57 severe oral mucositis 57 Inflammatory Arthritis 57 particularly SANCTURA XR 57 Peginterferon Alfa 2a 57 multicenter randomized controlled 57 Amrubicin 57 metastatic androgen independent 57 LAB CGRP 57 elevated transaminases 57 Cotara ® 57 Phase III ADT 57 novel orally inhaled 57 investigational immunotherapy 57 TASKi3 57 pegylated liposomal doxorubicin 57 Initiate Phase III 57 Prospective Randomized 57 patients receiving myelosuppressive 57 Matrix Phase 2b 57 hyperphenylalaninemia HPA due 57 AFREZZA TM 57 cromolyn sodium 57 delivers fluocinolone acetonide FA 57 pancreatic colon 57 Zemiva TM 57 HER2 positive metastatic 57 ZACTIMA 57 Pegylated Liposomal Doxorubicin 57 Randomized Double blind 57 Metastatic Colorectal Cancer 57 beta 1a 57 Enrolls First 57 Xelox 57 Metastatic Renal Cell Carcinoma 57 benign prostatic hyperplasia enlarged 57 NDA Submission 57 gastrin analogue TT 57 venous stasis ulcers 57 steroid refractory GvHD 57 orally inhaled 57 Immunotherapeutic 57 prostate cancer mCRPC 57 Golimumab 57 Early Relapsing Multiple 57 FDA Accepts 57 Phase 1b Clinical Trial 57 rALLy 57 IND Filing 57 PERSEUS 57 R lenalidomide 57 Stomatitis 57 induced macular edema 57 subcutaneous enoxaparin 57 INSPIRE Trial Phase III 57 REMINDER ORLive Presents 57 peginterferon alpha 2a 57 Advanced Renal Cell 57 treat benign prostatic 57 sedative pentobarbital sodium 57 Nonsurgical 57 Idiopathic Pulmonary Fibrosis 57 hypereosinophilic syndrome 57 Gemzar gemcitabine 57 taxane resistant 57 erythema nodosum 57 chronic thromboembolic pulmonary 57 ANN INTERN MED 57 taxane chemotherapy administered 57 Chronic Myeloid Leukemia 57 compound INCB# 57 CLARITY study 57 Azacitidine 57 leukemia AML 57 Sustained Efficacy 57 BR.# 57 Amgen denosumab 57 Treatment Shows Promise 57 oral deforolimus 57 ThermoDox R 57 metastatic adenocarcinoma 57 docetaxel cisplatin 57 patientswith 57 brand ciclesonide HFA 57 AERx ® 57 Phase IIb clinical trials 57 Tarvacin Anti Cancer 57 Shows Statistically Significant 57 CTAP# Capsules 57 AzaSite Otic 57 Initiates Phase 2b 57 Epratuzumab 57 acetonide FA 57 BENICAR HCT 57 refractory cutaneous T 57 estramustine 57 non nucleoside inhibitor 57 MAGE A3 ASCI 57 hyperplasia BPH 57 Dacogen injection 57 rhinitis sinusitis 57 de novo kidney transplant 57 systemic RNAi therapeutic 57 oncolytic virus therapies 57 pralatrexate injection folate analogue 57 Placebo Controlled Trial 57 IMPDH inhibitor 57 Therapy Reduces 57 Proellex TM 57 Lenocta TM 57 ALA PDT 57 HDL Selective Delipidation 57 TransVax 57 ritonavir boosted 57 moderate hepatic impairment 57 stage IIIb IV 57 Tumor Response 57 Adenoviral 57 dasatinib Sprycel 57 non porcine pancreatic 57 aldehyde dehydrogenase ALDH2 deficiency 57 asthma rheumatoid arthritis 57 antithymocyte globulin 57 ovarian esophageal 57 neutropenia febrile neutropenia 57 thalidomide Thalomid 57 Sprycel dasatinib 57 vaginal candidiasis 57 multicenter phase 57 Telik logo TELINTRA 57 Naive Patients 57 telomerase therapeutic 57 tumor angiogenesis inhibitors 57 irinotecan cisplatin 57 Fixed Dose 57 VESTASYNC 57 pancreatic gastric 57 R bortezomib 56 phase IIb clinical 56 Commence Phase 56 ovarian colon 56 proprietary intravenous formulation 56 metastatic colorectal carcinoma 56 Free Full Text 56 dasatinib Sprycel ® 56 PROSTASCINT R 56 preclinical efficacy 56 alpha1 antitrypsin deficiency 56 neck SCCHN 56 Appears Safe 56 pioglitazone hydrochloride 56 comparator arm 56 Panzem NCD 56 Romidepsin 56 NU# direct 56 MVA MUC1 IL2 56 ISTODAX ® 56 FOLOTYN ® 56 gets USFDA nod 56 Limb Ischemia 56 IV Busulfex 56 Hepatocellular Carcinoma HCC 56 brivanib 56 Vitaxin 56 vapreotide acetate 56 Delayed Graft Function 56 sorafenib tablets 56 Multiple Myeloma MM 56 Glufosfamide 56 octreotide implant 56 methylnaltrexone bromide 56 Fondaparinux 56 Pharmacodynamics 56 Adjunctive 56 intravascular hemolysis 56 somatostatin analog 56 mg administered orally 56 multicenter Phase II 56 Ixempra 56 CLL SLL 56 recurrent refractory 56 resectable pancreatic cancer 56 Diffuse Large B 56 Oral Mucositis 56 evaluating picoplatin 56 Recurrent Breast Cancer 56 FASLODEX 56 recurrent glioblastoma multiforme GBM 56 Aurora Kinase 56 underwent resection 56 LungAlert TM 56 Ophena 56 Denufosol 56 BRIM3 56 Engerix B 56 carcinoma mCRC 56 Microwave Ablation System 56 Female Stress Urinary 56 Archexin 56 relapsing remitting MS RRMS 56 Elestrin ® 56 sodium thiosulfate STS 56 Romiplostim 56 TBC# 56 Vicinium TM 56 TM Drug Eluting 56 Capesaris 56 recurrent glioblastoma 56 Xenografts 56 Vidaza R 56 ® natalizumab 56 Myelofibrosis 56 refractory myeloma 56 YONDELIS 56 EURIDIS 56 zonisamide SR 56 Syncria R 56 Ziprasidone 56 E1 INT TM 56 trastuzumab DM1 56 Telithromycin 56 sorafenib Nexavar 56 Primary Hypercholesterolemia 56 Randomized Clinical Trial 56 unresectable tumors 56 Malignant Glioma 56 Phase Ib II 56 Antiarrhythmic 56 adalimumab Humira 56 non CF bronchiectasis 56 drug NP2 Enkephalin 56 cancer mCRC 56 abacavir lamivudine 56 AAG geldanamycin analog 56 zoledronic acid Reclast 56 omacetaxine mepesuccinate 56 metastatic bone 56 recurrent NSCLC 56 baminercept 56 Plaque Psoriasis 56 IMiDs ® 56 antibody MT# 56 Dacogen decitabine 56 Vertebral Compression Fractures 56 RhuDex R 56 HCV RESPOND 2 56 TLK# 56 sirtuin inhibitor program 56 castration resistant hormone refractory 56 pelvic malignancies 56 HCV Hepatitis C 56 Randomised 56 pegylated interferon peg IFN 56 ELACYT 56 R sorafenib tablets 56 refractory ovarian cancer 56 PEGylated interferon beta 1a 56 Trofex TM 56 reslizumab 56 ChronVac C R 56 HDAC Inhibitor 56 cheilitis 56 intravesical infusion therapy 56 mGluR5 negative 56 NASH Huntington 56 acyclovir Lauriad R 56 adjuvant colon cancer 56 plus gemcitabine 56 Multiple Sclerosis Rheumatoid Arthritis 56 AERx R 56 Toremifene 56 Occlusive Disease 56 pharmacogenomic translational research 56 PYY #-# 56 evaluate ZFP Therapeutic 56 humanised monoclonal antibody 56 Cancer Cachexia 56 Aplidin 56 Testosterone MDTS ® 56 nephropathic cystinosis 56 cetrorelix pamoate 56 recurrent glioblastoma multiforme 56 Diabetic Ulcers 56 Chronic Lymphocytic Leukemia 56 receptor tyrosine kinase inhibitor 56 Multicenter 56 selective modulator 56 Cerebril TM 56 FOLFOX6 chemotherapy regimen 56 XL# administered orally 56 Carotid artery 56 Lymphocytic 56 FACTIVE ® 56 modified glutathione analog 56 Phase III multicenter 56 TG MV 56 PNP inhibitor 56 unfractionated heparin UFH 56 Velcade bortezomib 56 bavituximab monotherapy trial 56 sitaxsentan 56 Desvenlafaxine Succinate 56 Ovitrelle R Serostim 56 randomized controlled Phase 56 evaluating Actimmune 56 Kidney Transplant Patients 56 Platinol ® 56 osteoarthritis osteoporosis 56 Torisel temsirolimus 56 Hypertensive Patients 56 Accelerated Partial Breast Irradiation 56 phase III isavuconazole 55 dependent kinase inhibitor 55 papillary renal cell carcinoma 55 COPEGUS R 55 Opterone R 55 Sipuleucel T 55 diabetic peripheral neuropathic DPN 55 Biogen Genentech 55 pegylated liposomal doxorubicin PLD 55 treat chronic sinusitis 55 Aryplase 55 galiximab 55 urinary N telopeptide 55 bisoprolol 55 PROVENGE ® 55 #I TM# 55 denileukin diftitox 55 PSMA ADC 55 Nipent R 55 Hepatocellular Carcinoma 55 ZACTIMA TM ZD# 55 evaluating satraplatin 55 interferon gamma 1b 55 Receives Approvable Letter 55 Panzem R NCD 55 Muraglitazar 55 Chronic Heart Failure 55 Crofelemer budesonide foam 55 TTF Therapy 55 unresectable locally advanced 55 AKT inhibitor 55 novel tubulin binding 55 Anti VEGF 55 Trandolapril 55 Drug Eluting Stent System 55 SPEAR Study 55 Recurrent Glioblastoma 55 Localized Prostate Cancer 55 docetaxel Taxotere R 55 Solazed TM 55 ZK EPO 55 #mg dosing group 55 VNP#M 55 MEK Inhibitor 55 CYP#A# CYP#D# 55 JAK2 Inhibitor 55 trastuzumab Herceptin R 55 MIVI III 55 undergoing hematopoietic stem 55 plus prednisone 55 undergoing radical cystectomy 55 LUX Lung 55 Therapeutic Vaccine 55 XGEVA ™ 55 cutaneous T 55 Kinoid 55 Transurethral 55 kidney urologic 55 Post Herpetic Neuralgia 55 PEG interferon 55 Phase Ib clinical 55 complement inhibitor eculizumab 55 progressive metastatic prostate 55 lucinactant 55 Dementia Related Psychosis 55 Previously Untreated 55 AVN# Phase 55 Vidaza azacitidine 55 novel emulsion formulation 55 telomerase inhibitor drug 55 perioperatively 55 Ropinirole 55 Ophena TM 55 Hedgehog Pathway Inhibitor 55 precursor acute lymphoblastic 55 Submits Biologics License Application 55 allogeneic hematopoietic cell 55 IRX 2 55 Diabetic Macular Edema 55 Bronchopulmonary Dysplasia 55 TASKi2 55 Platelet Inhibition 55 chemotherapy cisplatin 55 5 Fluorouracil 55 acute mania 55 smoldering myeloma 55 AEG# 55 EINSTEIN DVT 55 Refractory Angina 55 noninferior 55 Hodgkin lymphoma HL 55 Non Invasive Treatment 55 Chronic HCV 55 Syndax Pharmaceuticals Inc. 55 surgical prophylaxis 55 oral rivaroxaban 55 Elagolix 55 MELAS 55 lumiliximab 55 ALTROPANE R 55 satraplatin Phase 55 Vaxfectin formulated 55 gastrointestinal toxicities 55 colorectal ovarian 55 QNEXA ® 55 HIV treatments Reyataz 55 cell lymphoma CTCL 55 gastrointestinal reflux 55 small molecule tyrosine 55 gastrointestinal stromal tumors GIST 55 Pruvel TM 55 Temodar temozolomide 55 pentostatin 55 tCGM system 55 AVASTIN 55 Sirolimus eluting 55 Arch Intern Med 55 PROSTVAC ® 55 Testosterone MDTS R 55 PDX pralatrexate 55 basal bolus regimen 55 miconazole Lauriad R 55 FEMALES SHOULD BE ADVISED 55 dextromethorphan quinidine 55 Protease Inhibitors 55 EVIZON TM 55 multicenter Phase 55 neuropathic pain spasticity 55 milnacipran HCl 55 EGFR TKI 55 Pamidronate 55 Picoplatin Efficacy After 55 Philadelphia Chromosome Positive 55 Factor VIIa 55 ORAL Sync 55 idiopathic membranous nephropathy 55 cyclophosphamide methotrexate 55 interferon alpha IFN 55 leukotriene receptor antagonist 55 Tanespimycin 55 Dyloject TM 55 Xyfid TM 55 Subgroup Analysis 55 Glioblastoma Multiforme 55 UPLYSO 55 Deforolimus 55 accumulate preferentially 55 Drug Shows Promise 55 STRIDE PD 55 Randomized Double Blind 55 Unigene nasal calcitonin 55 Phase 1a clinical 55 Personalized Immunotherapy 55 mRCC 55 Thromboembolism 55 ViaDerm hPTH #-# 55 desvenlafaxine succinate 55 Enzastaurin 55 huN# DM1 55 Immunomedics Announces 55 parathyroid carcinoma 55 interstitial cystitis IC 55 FluCAM arm 55 Selective Internal 55 Glatiramer Acetate 55 evaluating mipomersen 55 OvaRex 55 Doxil ® 55 DIRECT Trial 55 Fingolimod 55 neoplasias 55 tinea versicolor 55 PPAR gamma agonist 55 squamous non 55 steroid refractory ulcerative 55 allosteric modulator NAM 55 Rheumatoid 55 everolimus eluting 55 Myocardial Perfusion Imaging 55 preclinical pharmacokinetic 55 molecular imaging radiopharmaceutical 55 artery stenosis 55 Atypical Hemolytic Uremic Syndrome 55 Dose Escalation Study 55 Ribavirin causes 55 daily subcutaneous injections 55 metastatic gastric 55 huC# DM4 55 NicVAX TM 55 Teva Provides Update 55 advanced metastatic renal 55 Roflumilast 55 aflibercept VEGF Trap 55 Ovidrel 55 R roscovitine CDK cyclin 55 selective phosphodiesterase 55 chronic rheumatic 55 oral picoplatin 55 Myocardial Infarction Study 55 Heart Failure Patients 55 Ovarian Cancers 55 angiotensin analog 55 Serostim ® 55 gastrointestinal stromal 55 Intravenous immunoglobulin 55 evaluating carfilzomib 55 Epothilone D 55 MCSP respectively 55 GERD migraine headaches 55 Silodosin 55 briakinumab 55 benign prostatic hypertrophy BPH 55 Provectus Pharmaceuticals specializes 55 endoscopic autofluorescence imaging 55 intravenous bolus injection 55 targeted radiotherapeutic 55 MVA nef 55 Licenses Novel 55 PF # [002] 55 sacral nerve stimulation 55 agonistic human 55 Adenoma 55 Placebo controlled 55 Uterine Cancer 55 thrombocytosis 55 Cerebral Amyloid Angiopathy 54 Clinical Efficacy 54 orally administered inhibitor 54 SinuNase TM 54 Nexavar sorafenib 54 Spiegelmer ® 54 Lodotra TM 54 Fibrin Patch 54 Pfizer Camptosar 54 Alvine Pharmaceuticals 54 multicenter multinational 54 targeting miR 54 DepoCyt 54 prostate cancer HRPC 54 distal embolization thrombus formation 54 indications Dupuytren 54 Hormone Receptor Positive 54 Interferon beta 1b 54 Initiates Phase 54 PANVAC VF 54 visceral metastases 54 Vertex hepatitis C 54 overactive bladder VANTAS R 54 Treatment Experienced 54 stated Michelle Berrey 54 ovarian breast 54 pertuzumab 54 abacavir Ziagen 54 osteolytic bone disease 54 refractory acute myeloid 54 DG# compounds targeting 54 Postmenopausal 54 treat secondary hyperparathyroidism 54 relapsed ALL 54 Plaquenil 54 omalizumab Xolair 54 ACAPODENE 54 Cardiac Resynchronization 54 Xcytrin R 54 Knee Osteoarthritis 54 Neurodegenerative 54 oral nucleoside analogue